I was wondering whether the recent run up past $2 was due to optimism regarding upcoming phase 2 results vs the MM's setting up an exit strategy (at a higher share price) for insiders to unload shares. It appears that the latter is the case.
True, but I'm not sure in this case. Ganax spares the progesterone receptor--which makes it safer for long term use (no prednisone-like steroidal side effects)-- but it is likely SAGE 547's effect on this receptor which makes it effective in PPD. Ganax may not work for PPD.
Hey jr, AVXL has been on quite a run, and it could continue. Also, the biotech sector as a whole has has a good last few days. Maybe the bottom is in, and a run is just starting. However, the IBB has been in a descending pattern, making lower highs each time. So the pattern is still bearish overall, until it breaks. At least 240 on the IBB has held three times.
Thanks, I'll check out CRMD. Yes, I have a very small position in AVXL.
Despite the biotech implosion going on for over a year now, overall I am still well in the green, mostly due to my gains last year in AVXL. But I've given back a significant chunk of those gains in catastrophes like MRNS, IDRA, and a couple of others. Like practically everyone else, I should have stayed on the sidelines in 2016.
Hey daw. You're probably right. But regarding SAGE's PPD trial, women have been using progesterone-like supplements (off label, available online and in health food stores) with many reports of success. So maybe SAGE's PPD trial has a chance.
Hey Jr... Good move getting out of that one. I sure thought MRNS was a better bet than GALE (at least it has a well-known MOA, but not good enough, obviously).
Anyway, watch AVXL, retailers are running it up like they did with GALE, for interim results coming in July.
I'm laying low now, as I've lost too much money this year to gamble any more on binary events.
Well, Ed, you're right about that. Our policies in the Middle East have been terrible (Iraq war, then abandoning the region, support of Arab "springs" which overthrew stable governments, leading to the birth of ISIS and then the refugee problem, the Iran nuclear deal, etc.).
(As for Israel, perhaps in the long term our incompetence has been a blessing in disguise. Their enemies are in disarray. And very slowly Israel been decreasing their dependence on the U.S. alone by increasing ties with Russia and India. Probably a good move for them in the long term.)
A currency war may not necessarily cause a collapse in the US stock market. If the dollar gets significantly devalued, the stock market could in fact rise (of course, we still lose because it the stock price will be in devalued dollars). Gold could explode up 5X, but U.S. stock market could still slowly rise at the same time.
K thanks. Secondary was met, but still disappointed that the researchers weren't impressed enough to grade any improvement in CGI at all. (Minocycline had a CGI-I score only a half point better than baseline, and that trial was hailed as a big success having met the primary endpoint).
Hey, DAW-- If the parents like what they saw, I would think they would reflect that on the CGI grade. I still can't understand how the parents/researchers liked what they saw but didn't grade that improvement on the CGI scale, which is just a subjective grade from 1-10 on the overall picture...
Hey Andre, there is definitely still a shot here. But how could they not have any improvement on CGI? Everyone concluded (family and doctors) that overall they were no better. That's what CGi is.... Even Minocycline did meet that endpoint.
Mixed results, not a bust. But definitely will not get an FDA approval without another trial. With no improvement in the CGI-- clinical global impression-- the FDA will need to be convinced that this drug doesn't just dope them up. Why is it any different than, say, Valium? This is where the presentation on cortical function needs to show that Ganax doesn't decrease cortical function like the Benzos (Valium, etc) do.
What is curious to me is that they didn't halt the stock in the after hours today. I recall many times that when a company announced that results would be released the next morning, the stock was halted the evening before (like CLDN and others). It allows both longs and shorts to adjust their position. Somewhat odd.
Yes, so my guess is positive news. The question is how positive. The primary endpoint is a pretty easy target. Not sure about all the secondary ones.